long intergenic non-protein coding RNA 930Genealiases: []
Q-omics provides the consensus-scored LINC00930 profile across patient tissues and cancer cell-line models. LINC00930 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, LINC00930 is differentially expressed in 12, with the highest sampling consensus in COAD. Additionally, LINC00930 RNA expression shows 14,121 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UVM, and COAD as cancer lineages where LINC00930 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC00930 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC00930 survival associations across molecular data types. LINC00930 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC00930 RNA expression–survival associations across cancer types. High LINC00930 expression shows unfavorable associations in UVM and KIRC, but favorable associations in BLCA, PAAD, UCEC and LIHC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for LINC00930 RNA expression.
This table summarizes LINC00930 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC00930. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC00930 shows lower tumor expression in COAD, LUSC, LUAD and THCA and higher tumor expression in CHOL and KICH. The COAD box plot shows higher LINC00930 RNA expression in normal versus tumor tissue (log2 FC = −0.484, t-test p < 0.001).
This table shows molecular features associated with LINC00930 in patient tissues and cancer cell lines. In patient samples, LINC00930 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
